[FBIO] Fortress Biotech, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.37 Change: 0.15 (6.76%)

chart FBIO

Refresh chart

Strongest Trends Summary For FBIO

FBIO is in the medium-term up 152% above S&P in 3 months. In the long-term down -59% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.36 M Cash From Investing Activities-1.36 M Cash From Operating Activities-8.83 M Gross Profit
Net Profit-12.06 M Operating Profit-12.07 M Total Assets90.45 M Total Current Assets69.61 M
Total Current Liabilities5.93 M Total Debt24.01 M Total Liabilities30.3 M Total Revenue500 K
Technical Data
High 52 week5.35 Low 52 week0.57 Last close2.19 Last change1.86%
RSI45.83 Average true range0.15 Beta1.24 Volume144.58 K
Simple moving average 20 days6.34% Simple moving average 50 days52.93% Simple moving average 200 days13.01%
Performance Data
Performance Week0.46% Performance Month106.6% Performance Quart55.32% Performance Half8.42%
Performance Year-42.52% Performance Year-to-date154.65% Volatility daily9.97% Volatility weekly22.29%
Volatility monthly45.69% Volatility yearly158.26% Relative Volume321.39% Average Volume611.43 K
New High New Low


2019-03-18 07:30:00 | Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

2019-03-18 07:30:00 | Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights

2019-03-14 10:42:02 | All You Need to Know About Fortress Biotech FBIO Rating Upgrade to Strong Buy

2019-03-13 08:30:00 | Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

2019-03-12 07:30:00 | Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

2019-02-28 08:41:01 | Sarepta SRPT Jumps: Stock Rises 8.3%

2019-02-20 08:30:00 | Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus C134 to Treat Glioblastoma Multiforme

2019-02-12 09:00:00 | Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation

2019-02-11 07:30:00 | Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen a Cipla subsidiary

2019-02-05 10:30:00 | Biotech on the Brink of Breaking Out

2019-02-01 08:35:00 | Fortress BioTech, Late Stage Development Progress and Caelum Partnership with Alexion

2019-02-01 08:30:00 | Biotechs to Put on Your Watchlist

2019-01-31 09:20:00 | 4 Biotech Stocks Making Moves On Thursday 1/31/19

2019-01-31 06:30:00 | Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

2019-01-28 10:05:00 | ATXI: How Much Are CVRs Worth?

2019-01-27 08:10:35 | Have Insiders Been Selling Fortress Biotech, Inc. NASDAQ:FBIO Shares?

2019-01-02 07:20:00 | Report: Exploring Fundamental Drivers Behind Energy Transfer LP, Cable One, DTE Energy, Civitas Solutions, Owens Realty Mortgage, and Fortress Biotech — New Horizons, Emerging Trends, and Upcoming Developments

2018-12-21 13:17:18 | Fortress Biotech Recaps Corporate Highlights and Achievements in 2018

2018-12-20 08:30:00 | Mustang Bio Receives Orphan Drug Designation for MB-102 CD123 CAR T for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

2018-12-19 08:00:00 | Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

2018-12-12 14:58:17 | Should You Worry About Fortress Biotech, Inc.’s NASDAQ:FBIO CEO Pay?

2018-11-20 08:37:01 | Fortress Biotech FBIO in Focus: Stock Moves 6.5% Higher

2018-11-19 08:00:00 | B. Riley Financial Enters a Definitive Agreement to Purchase Fortress Biotech’s Stake in National Holdings Corporation

2018-11-19 08:00:00 | Fortress Biotech Announces Agreement to Sell Its Majority Stake in National Holdings Corporation to NHC Holdings, LLC, a wholly-owned subsidiary of B. Riley Financial

2018-11-19 08:00:00 | B. Riley Financial Enters Agreement to Purchase Fortress Biotech’s Stake in National Holdings

2018-11-14 08:20:00 | Consolidated Research: 2018 Summary Expectations for Franco-Nevada, CPS Technologies, I.D., Fortress Biotech, Avalon, and Key Tronic — Fundamental Analysis, Key Performance Indications

2018-11-13 06:30:00 | InvaGen a Cipla subsidiary Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

2018-11-09 08:50:01 | Fortress Biotech FBIO Reports Q3 Loss, Lags Revenue Estimates

2018-11-09 07:47:15 | Fortress Biotech: 3Q Earnings Snapshot

2018-11-09 07:30:00 | Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

2018-11-01 11:28:03 | Will Fortress Biotech FBIO Report Negative Earnings Next Week? What You Should Know

2018-10-30 08:00:00 | Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope

2018-10-15 08:00:00 | Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer

2018-10-12 15:13:07 | What Does Fortress Biotech Inc’s NASDAQ:FBIO Ownership Structure Look Like?

2018-10-01 08:00:00 | Mustang Bio to Present at 8th Annual Partnering Forum at Cell & Gene Meeting on the Mesa

2018-09-27 08:00:00 | Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference

2018-09-27 07:30:00 | National Announces Expansion of Equity Research Team

2018-09-26 08:05:00 | Fortress Biotech, Business Model Review, Pipeline, Analysts Opinion and Target

2018-09-12 08:30:00 | Fortress Biotech Announces Publication of Preclinical Data on AAV-ATP7A Gene Therapy Combined with CUTX-101 Copper Histidinate for Menkes Disease in Molecular Therapy: Methods & Clinical Development

2018-09-06 07:30:00 | Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

2018-09-04 07:15:00 | Mustang Bio Announces Presentations on CAR T Therapies at 4th Annual CAR-TCR Summit 2018

2018-08-30 08:00:00 | Mustang Bio to Participate in September Investor Conferences

2018-08-30 08:00:00 | Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-20 07:33:43 | National Holdings Corporation Announces Expansion of Capital Markets Team

2018-08-14 07:30:00 | Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

2018-08-13 16:15:00 | Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

2018-08-13 08:00:00 | Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

2018-08-13 08:00:00 | Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency

2018-08-13 07:41:41 | St. Jude and Mustang Bio enter into exclusive worldwide license agreement

2018-08-09 20:00:12 | Fortress Biotech FBIO Reports Q2 Loss, Tops Revenue Estimates